Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3: a pre-clinical pilot study.
about
Electrophysiological Perspectives on Hybrid Ablation of Atrial Fibrillation.HERG K+ channel-dependent apoptosis and cell cycle arrest in human glioblastoma cellsPlasma phospholipid saturated fatty acids and incident atrial fibrillation: the Cardiovascular Health Study.Atrial fibrillation complicated by heart failure induces distinct remodeling of calcium cycling proteinsBiological Heart Rate Reduction Through Genetic Suppression of Gα(s) Protein in the Sinoatrial Node.Regulation of apoptosis in HL-1 cardiomyocytes by phosphorylation of the receptor tyrosine kinase EphA2 and protection by lithocholic acid.The Use of Gene Therapy for Ablation of Atrial Fibrillation.Mechanisms of zolpidem-induced long QT syndrome: acute inhibition of recombinant hERG K(+) channels and action potential prolongation in human cardiomyocytes derived from induced pluripotent stem cellsRecent insights into the role of the autonomic nervous system in the creation of substrate for atrial fibrillation: implications for therapies targeting the atrial autonomic nervous system.Biological Therapies for Atrial Fibrillation: Ready for Prime Time?Cyclic nucleotide phosphodiesterase 3A1 protects the heart against ischemia-reperfusion injury.Gene therapy to restore electrophysiological function in heart failure.Gene therapy to treat cardiac arrhythmias.Novel ion channel targets in atrial fibrillation.Improving Atrial Fibrillation Therapy: Is There a Gene for That?Gene Therapy for Atrial Fibrillation in Heart Failure.Current state of the art for cardiac arrhythmia gene therapy.Constitutive Expression of a Dominant-Negative TGF-β Type II Receptor in the Posterior Left Atrium Leads to Beneficial Remodeling of Atrial Fibrillation Substrate.TREK-1 (K2P2.1) K+ channels are suppressed in patients with atrial fibrillation and heart failure and provide therapeutic targets for rhythm control.Increased preoperative serum apoptosis marker fas ligand correlates with histopathology and new-onset of atrial fibrillation in patients after cardiac surgery.Anti-KCNQ1 K⁺ channel autoantibodies increase IKs current and are associated with QT interval shortening in dilated cardiomyopathy.Inverse remodelling of K2P3.1 K+ channel expression and action potential duration in left ventricular dysfunction and atrial fibrillation: implications for patient-specific antiarrhythmic drug therapy.
P2860
Q28073160-17D1B1AE-4BC4-4587-8E7F-7949064E08E4Q28539628-8F6E6BC6-D595-42FC-B6FC-6CE16FB16062Q35021951-FE1EF9B6-91F6-460F-9566-A8334A268703Q35180988-2E302F8C-6185-43F7-8779-199C0EB24619Q36366373-C55D5DF7-2D88-4EE4-96CA-2A7DC9BC00F3Q36446536-97F536D4-7351-428D-916A-DC48CFB32E12Q36458906-8DB4056C-42F6-44AC-9B4E-6FBDE22F5C33Q36675819-EE9793BF-BF58-4CCA-8881-9624C20DCE9AQ36713691-F35865C7-28E7-414F-BA30-460227860460Q36934761-C726C83B-156B-4C05-856F-1EB454AB3EACQ37407038-FBE9ED13-5C7F-43E0-8525-3627BF77E96CQ38416938-48B91BB9-CBA3-40E0-BFF4-3EBB491E5401Q38444909-584B7F46-769A-443B-9DEE-7F6FC75FCF27Q38751315-E7C2192E-6016-496F-8AB6-B2A30A38CA52Q38828102-0B81A5FD-9E95-41A3-AE1E-6821D1A4A6CDQ39332399-B4EA9B77-A848-42FC-987C-DE4BA55912D6Q39392472-87D9CF5B-FCBA-4509-A12F-EC15C4806426Q39741408-6E84819F-2815-44F7-970E-B2B4F4E70948Q42008383-0CBC083A-545F-4822-BF1E-537DF574997BQ45900808-57050B50-D8D7-4677-99AE-7166479B73A9Q46670824-CC5C28D9-274C-4C7F-8BB9-3DA5C842FC11Q48744881-E4F94891-504D-43FE-8AA4-B42360792BC4
P2860
Suppression of persistent atrial fibrillation by genetic knockdown of caspase 3: a pre-clinical pilot study.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年学术文章
@wuu
2011年学术文章
@zh
2011年学术文章
@zh-cn
2011年学术文章
@zh-hans
2011年学术文章
@zh-my
2011年学术文章
@zh-sg
2011年學術文章
@yue
2011年學術文章
@zh-hant
name
Suppression of persistent atri ...... 3: a pre-clinical pilot study.
@en
Suppression of persistent atri ...... 3: a pre-clinical pilot study.
@nl
type
label
Suppression of persistent atri ...... 3: a pre-clinical pilot study.
@en
Suppression of persistent atri ...... 3: a pre-clinical pilot study.
@nl
prefLabel
Suppression of persistent atri ...... 3: a pre-clinical pilot study.
@en
Suppression of persistent atri ...... 3: a pre-clinical pilot study.
@nl
P2093
P2860
P356
P1476
Suppression of persistent atri ...... 3: a pre-clinical pilot study.
@en
P2093
Alexander Bauer
Dierk Thomas
Frederik Voss
Hugo A Katus
Kamilla Kelemen
Kerstin Trappe
Olympia Bikou
Patrick Lugenbiel
Rüdiger Becker
P2860
P304
P356
10.1093/EURHEARTJ/EHR269
P577
2011-07-23T00:00:00Z